Payment overview · 2025
General Payments
$23,969.26
55 reported records · 22 companies
Healthcare provider profile · identity verified
Stephen Arndt, M.D.
Allopathic & Osteopathic Physicians|Orthopaedic Surgery · JACKSONVILLE, FL · NPI 1346301322
Verified facts
What the public records show
CMS Open Payments records show Stephen Arndt, M.D. received $23,969.26 in general payments during 2025 across 55 reported records.
Medline Industries LP accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medline Industries LP | Unresolved — no canonical attribution shown | $7,467.60 | 31.1% | 8 | 2025 |
| Accufix Surgical Inc. | Unresolved — no canonical attribution shown | $6,018.01 | 25.1% | 2 | 2025 |
| Arthrex, Inc. | Unresolved — no canonical attribution shown | $2,500.00 | 10.4% | 1 | 2025 |
| Biocomposites Inc | Unresolved — no canonical attribution shown | $2,187.70 | 9.1% | 5 | 2025 |
| Intelivation Technologies, LLC | Unresolved — no canonical attribution shown | $2,000.00 | 8.3% | 4 | 2025 |
| Anika Therapeutics, Inc. | Unresolved — no canonical attribution shown | $1,385.83 | 5.8% | 4 | 2025 |
| Metric Medical Devices, Inc. | Unresolved — no canonical attribution shown | $1,000.00 | 4.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $297.31 | 1.2% | 11 | 2025 |
| Paragon 28, Inc. | Unresolved — no canonical attribution shown | $286.69 | 1.2% | 3 | 2025 |
| Voom Medical Devices, Inc. | Unresolved — no canonical attribution shown | $250.14 | 1.0% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $113.48 | 0.5% | 1 | 2025 |
| TheraMicro, Inc. | Unresolved — no canonical attribution shown | $79.03 | 0.3% | 1 | 2025 |
| Novastep Inc. | Unresolved — no canonical attribution shown | $74.76 | 0.3% | 1 | 2025 |
| Team 1, LLC | Unresolved — no canonical attribution shown | $56.08 | 0.2% | 2 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $50.94 | 0.2% | 1 | 2025 |
| EBI, LLC | Unresolved — no canonical attribution shown | $48.87 | 0.2% | 1 | 2025 |
| Highridge Medical LLC | Unresolved — no canonical attribution shown | $48.87 | 0.2% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $33.78 | 0.1% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $22.79 | 0.1% | 2 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $16.94 | 0.1% | 1 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $15.44 | 0.1% | 1 | 2025 |
| Innovation Technologies Inc | Unresolved — no canonical attribution shown | $15.00 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $18,400.00 | 12 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000.00 | 3 |
| Food and Beverage | $2,390.04 | 39 |
| Travel and Lodging | $179.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Medline Industries, Inc. Normalized: medline industries inc |
Device | Medline Industries LP | $6,750.00 | 3 | 2025 |
Source payment records
|
|||||
| ACCU-JOINT Normalized: accu joint |
Device | Accufix Surgical Inc. | $6,018.01 | 2 | 2025 |
Source payment records
|
|||||
| MEDLINE UNITE Normalized: medline unite |
Device | Medline Industries LP | $2,250.00 | 1 | 2025 |
Source payment records
|
|||||
| Medline Normalized: medline |
Device | Medline Industries LP | $2,250.00 | 1 | 2025 |
Source payment records
|
|||||
| PENDING Normalized: pending |
Device | Medline Industries LP | $2,250.00 | 1 | 2025 |
Source payment records
|
|||||
| Stimulan Normalized: stimulan |
Device | Biocomposites Inc | $2,187.70 | 5 | 2025 |
Source payment records
|
|||||
| Integrity Implant Normalized: integrity implant |
Device | Anika Therapeutics, Inc. | $1,385.83 | 4 | 2025 |
Source payment records
|
|||||
| LINK External Fixator Normalized: link external fixator |
Device | Metric Medical Devices, Inc. | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Apex 3D Normalized: apex 3d |
Device | Paragon 28, Inc. | $286.69 | 3 | 2025 |
Source payment records
|
|||||
| REVCON INSTRUMENT KIT, STERILE Normalized: revcon instrument kit sterile |
Device | Voom Medical Devices, Inc. | $250.14 | 2 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 3DI Normalized: ortholoc 3di |
Device | Stryker Corporation | $170.57 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY ADAPTIS Normalized: infinity adaptis |
Device | Stryker Corporation | $108.53 | 8 | 2025 |
Source payment records
|
|||||
| BIOMET SPINALPAK NON-INVASIVE SPINE FUSION STIMULATOR SYSTEM Normalized: biomet spinalpak non invasive spine fusion stimulator system |
Device | EBI, LLC, Highridge Medical LLC | $97.74 | 2 | 2025 |
Source payment records
|
|||||
| TekBrace Solo Normalized: tekbrace solo |
Device | TheraMicro, Inc. | $79.03 | 1 | 2025 |
Source payment records
|
|||||
| NEXIS Normalized: nexis |
Device | Novastep Inc. | $74.76 | 1 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $50.94 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $22.79 | 2 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $18.21 | 2 | 2025 |
Source payment records
|
|||||
| MOTOBAND Normalized: motoband |
Device | DePuy Synthes Sales Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| IRRISEPT Normalized: irrisept |
Device | Innovation Technologies Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 314 | 180 |
| Lidocaine | Lidocaine | 196 | 147 |
| Methylprednisolone | Methylprednisolone | 71 | 52 |
| Calcipotriene | Calcipotriene | 53 | 47 |
| Ciclopirox | Ciclopirox | 47 | 39 |
| Gabapentin | Gabapentin | 47 | 27 |
| Ketoconazole | Ketoconazole | 44 | 41 |
| Ibuprofen | Ibuprofen | 36 | 23 |
| Mupirocin | Mupirocin Calcium | 32 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 15 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Mefenamic Acid | Mefenamic Acid | 14 | 12 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | 11 |
| Tramadol Hcl | Tramadol Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,969.26 · 55 records | Medline Industries LP | ACCU-JOINT, AUGMENT INJECTABLE, Apex 3D, BIOMET SPINALPAK NON-INVASIVE SPINE FUSION STIMULATOR SYSTEM, INFINITY ADAPTIS, IRRISEPT, Integra, Integra Dermal Regeneration Template, Integrity Implant, LINK External Fixator, MEDLINE UNITE, MOTOBAND, Medline, Medline Industries, Inc., NEXIS, ORTHOLOC 3DI, PENDING, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, PRIMATRIX, Physio-Stim, REVCON INSTRUMENT KIT, STERILE, Stimulan, TMC NANOPLASTY SYSTEM, TekBrace Solo | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error